Standard treatment for active tuberculosis (TB) requires drug treatment with at least four
drugs over six months. Shorter-duration therapy would mean less need for strict adherence …

Background Given the persistently high global burden of tuberculosis, effective and shorter
treatment options are needed. We explored the relationship between relapse and treatment …

There is a critical need for improved and shorter tuberculosis (TB) treatment. Current in vitro
models of TB, while valuable, are poor predictors of the antibacterial effect of drugs in vivo …

Background Improvement in tuberculosis treatment regimens requires selection of
antibiotics and dosing schedules from a large design space of possibilities. Incomplete …

One critical approach to preclinical evaluation of anti-tuberculosis (anti-TB) drugs is the
study of correlations between drug exposure and efficacy in animal TB infection models …

Tuberculosis (TB) kills more people than any other infectious disease. Challenges for
developing better treatments include the complex pathology due to within-host immune …

Disappointing results of recent tuberculosis chemotherapy trials suggest that knowledge
gained from preclinical investigations was not utilized to maximal effect. A mouse‐to‐human …

One problem associated with regimen-based development of antituberculosis (anti-TB)
drugs is the difficulty of a systematic and thorough in vivo evaluation of the large number of …

This work assesses the impact of the first line drug regimen on active disease control under
the stipulated time of tuberculosis (TB) treatment. In an effort to understand why a robust …

Short-course regimens for multidrug-resistant tuberculosis (MDR-TB) are urgently needed.
Limited data suggest that the new drug bedaquiline (BDQ) may have the potential to shorten …